Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes

Kei Ichi Ozaki, Midori Awazu, Mayuko Tamiya, Yuka Iwasaki, Aya Harada, Satomi Kugisaki, Susumu Tanimura, Michiaki Kohno

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Extracellular signal-regulated kinase (ERK) has been implicated in the development of insulin resistance associated with obesity and type 2 diabetes mellitus. We have now examined the potential of pharmacological targeting of the ERK pathway with MEK (ERK kinase) inhibitors (PD184352 and PD0325901) for the treatment of obesity-associated insulin resistance. The effects of PD184352 and PD0325901 on the expression of adipocytokines and lipolysis activity were thus examined in 3T3-L1 adipocytes maintained in long-term culture as a model of adipocyte hypertrophy. Leptin receptor-deficient (db/db) mice and high-fat diet-fed KKAy mice, both of which are models of type 2 diabetes, were also treated orally with PD184352 to examine its effects on the diabetic condition. ERK activity was increased in hypertrophic 3T3-L1 adipocytes as well as in adipose tissue of db/db mice and high-fat diet-fed KKAy mice, and this enhanced ERK signaling was associated with dysregulation of adipocytokine expression and increased lipolysis activity. Specific blockade of the ERK pathway in hypertrophic 3T3-L1 adipocytes by MEK inhibitors ameliorated the dysregulation of adipocytokine expression and suppressed the enhanced lipolysis activity. Furthermore, repeated oral administration of PD184352 normalized hyperglycemia and hyperlipidemia and improved insulin sensitivity and glucose tolerance in the diabetic mice. These results suggest that sustained activation of the ERK pathway in adipocytes is associated with the pathogenesis of type 2 diabetes and that selective blockade of this pathway with MEK inhibitors warrants further study as a promising approach to the treatment of insulin resistance and type 2 diabetes.

Original languageEnglish
Pages (from-to)E643-E651
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume310
Issue number8
DOIs
Publication statusPublished - 2016 Apr 15

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Type 2 Diabetes Mellitus
Insulin Resistance
Adipocytes
Adipokines
Lipolysis
Mitogen-Activated Protein Kinase Kinases
High Fat Diet
Therapeutics
Obesity
Leptin Receptors
Hyperlipidemias
Hyperglycemia
Hypertrophy
Oral Administration
Adipose Tissue
Phosphotransferases
Pharmacology
Glucose
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide

Keywords

  • Adipocyte
  • Adipocytokine
  • Extracellular signal-regulated kinase pathway
  • MEK inhibitor
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Medicine(all)
  • Physiology (medical)

Cite this

Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes. / Ozaki, Kei Ichi; Awazu, Midori; Tamiya, Mayuko; Iwasaki, Yuka; Harada, Aya; Kugisaki, Satomi; Tanimura, Susumu; Kohno, Michiaki.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 310, No. 8, 15.04.2016, p. E643-E651.

Research output: Contribution to journalArticle

Ozaki, Kei Ichi ; Awazu, Midori ; Tamiya, Mayuko ; Iwasaki, Yuka ; Harada, Aya ; Kugisaki, Satomi ; Tanimura, Susumu ; Kohno, Michiaki. / Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes. In: American Journal of Physiology - Endocrinology and Metabolism. 2016 ; Vol. 310, No. 8. pp. E643-E651.
@article{21382edf47cb49b09ae66b991a1a8264,
title = "Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes",
abstract = "Extracellular signal-regulated kinase (ERK) has been implicated in the development of insulin resistance associated with obesity and type 2 diabetes mellitus. We have now examined the potential of pharmacological targeting of the ERK pathway with MEK (ERK kinase) inhibitors (PD184352 and PD0325901) for the treatment of obesity-associated insulin resistance. The effects of PD184352 and PD0325901 on the expression of adipocytokines and lipolysis activity were thus examined in 3T3-L1 adipocytes maintained in long-term culture as a model of adipocyte hypertrophy. Leptin receptor-deficient (db/db) mice and high-fat diet-fed KKAy mice, both of which are models of type 2 diabetes, were also treated orally with PD184352 to examine its effects on the diabetic condition. ERK activity was increased in hypertrophic 3T3-L1 adipocytes as well as in adipose tissue of db/db mice and high-fat diet-fed KKAy mice, and this enhanced ERK signaling was associated with dysregulation of adipocytokine expression and increased lipolysis activity. Specific blockade of the ERK pathway in hypertrophic 3T3-L1 adipocytes by MEK inhibitors ameliorated the dysregulation of adipocytokine expression and suppressed the enhanced lipolysis activity. Furthermore, repeated oral administration of PD184352 normalized hyperglycemia and hyperlipidemia and improved insulin sensitivity and glucose tolerance in the diabetic mice. These results suggest that sustained activation of the ERK pathway in adipocytes is associated with the pathogenesis of type 2 diabetes and that selective blockade of this pathway with MEK inhibitors warrants further study as a promising approach to the treatment of insulin resistance and type 2 diabetes.",
keywords = "Adipocyte, Adipocytokine, Extracellular signal-regulated kinase pathway, MEK inhibitor, Type 2 diabetes",
author = "Ozaki, {Kei Ichi} and Midori Awazu and Mayuko Tamiya and Yuka Iwasaki and Aya Harada and Satomi Kugisaki and Susumu Tanimura and Michiaki Kohno",
year = "2016",
month = "4",
day = "15",
doi = "10.1152/ajpendo.00445.2015",
language = "English",
volume = "310",
pages = "E643--E651",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "8",

}

TY - JOUR

T1 - Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes

AU - Ozaki, Kei Ichi

AU - Awazu, Midori

AU - Tamiya, Mayuko

AU - Iwasaki, Yuka

AU - Harada, Aya

AU - Kugisaki, Satomi

AU - Tanimura, Susumu

AU - Kohno, Michiaki

PY - 2016/4/15

Y1 - 2016/4/15

N2 - Extracellular signal-regulated kinase (ERK) has been implicated in the development of insulin resistance associated with obesity and type 2 diabetes mellitus. We have now examined the potential of pharmacological targeting of the ERK pathway with MEK (ERK kinase) inhibitors (PD184352 and PD0325901) for the treatment of obesity-associated insulin resistance. The effects of PD184352 and PD0325901 on the expression of adipocytokines and lipolysis activity were thus examined in 3T3-L1 adipocytes maintained in long-term culture as a model of adipocyte hypertrophy. Leptin receptor-deficient (db/db) mice and high-fat diet-fed KKAy mice, both of which are models of type 2 diabetes, were also treated orally with PD184352 to examine its effects on the diabetic condition. ERK activity was increased in hypertrophic 3T3-L1 adipocytes as well as in adipose tissue of db/db mice and high-fat diet-fed KKAy mice, and this enhanced ERK signaling was associated with dysregulation of adipocytokine expression and increased lipolysis activity. Specific blockade of the ERK pathway in hypertrophic 3T3-L1 adipocytes by MEK inhibitors ameliorated the dysregulation of adipocytokine expression and suppressed the enhanced lipolysis activity. Furthermore, repeated oral administration of PD184352 normalized hyperglycemia and hyperlipidemia and improved insulin sensitivity and glucose tolerance in the diabetic mice. These results suggest that sustained activation of the ERK pathway in adipocytes is associated with the pathogenesis of type 2 diabetes and that selective blockade of this pathway with MEK inhibitors warrants further study as a promising approach to the treatment of insulin resistance and type 2 diabetes.

AB - Extracellular signal-regulated kinase (ERK) has been implicated in the development of insulin resistance associated with obesity and type 2 diabetes mellitus. We have now examined the potential of pharmacological targeting of the ERK pathway with MEK (ERK kinase) inhibitors (PD184352 and PD0325901) for the treatment of obesity-associated insulin resistance. The effects of PD184352 and PD0325901 on the expression of adipocytokines and lipolysis activity were thus examined in 3T3-L1 adipocytes maintained in long-term culture as a model of adipocyte hypertrophy. Leptin receptor-deficient (db/db) mice and high-fat diet-fed KKAy mice, both of which are models of type 2 diabetes, were also treated orally with PD184352 to examine its effects on the diabetic condition. ERK activity was increased in hypertrophic 3T3-L1 adipocytes as well as in adipose tissue of db/db mice and high-fat diet-fed KKAy mice, and this enhanced ERK signaling was associated with dysregulation of adipocytokine expression and increased lipolysis activity. Specific blockade of the ERK pathway in hypertrophic 3T3-L1 adipocytes by MEK inhibitors ameliorated the dysregulation of adipocytokine expression and suppressed the enhanced lipolysis activity. Furthermore, repeated oral administration of PD184352 normalized hyperglycemia and hyperlipidemia and improved insulin sensitivity and glucose tolerance in the diabetic mice. These results suggest that sustained activation of the ERK pathway in adipocytes is associated with the pathogenesis of type 2 diabetes and that selective blockade of this pathway with MEK inhibitors warrants further study as a promising approach to the treatment of insulin resistance and type 2 diabetes.

KW - Adipocyte

KW - Adipocytokine

KW - Extracellular signal-regulated kinase pathway

KW - MEK inhibitor

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84983761022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983761022&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00445.2015

DO - 10.1152/ajpendo.00445.2015

M3 - Article

AN - SCOPUS:84983761022

VL - 310

SP - E643-E651

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 8

ER -